



The Formula for 100% Blood Pressure Control: Guidelines, Data & Tools in Action


September 22nd, 2025



COMMUNITY HEALTH CARE ASSOCIATION of New York State chcanys.org

Housekeeping

- Welcome!
- Let's get to know each other - Take a moment to introduce yourself in the chat!
- **Please change your name to your full First and Last Name**
- **Please add your Health Center/Organization Name next to your name!**



Speakers



Andrew Moran, MD, MPH

Associate Professor of Medicine, Columbia University

Director, Global Hypertension Control, Resolve to Save Lives



Amelia Fox

Senior Clinical Improvement Specialist, Azara Healthcare





Bridging the gap: Translating 2025 US hypertension guidelines into practice

Andrew E. Moran, MD, MPH


Associate Professor of Medicine, Columbia University

Director, Global Hypertension Control, Resolve to Save Lives

Motivation

Hypertension control = lives saved

- Of all primary care preventive services, **hypertension control saves the most lives**




Hypertension in the US population*

- Fewer than 1 in 4 US adults with HTN have their BP controlled <130/80 mmHg (less than half are <140/90).

Estimated Hypertension Prevalence, Treatment, and Control (Blood Pressure <130/80 mm Hg) Among US Adults^a

Applying the criteria from the American College of Cardiology and American Heart Association's (ACC/AHA) 2017 Hypertension Clinical Practice Guideline - NHANES 2017- March 2020



Data source: National Center for Health Statistics, Centers for Disease Control and Prevention, National Health and Nutrition Examination Survey (NHANES) 2017-March 2020. Definitions: ACC/AHA criteria adapted from Ritchey MD, Gillespie C, Wozniak G, et al. Potential need for expanded pharmacologic treatment and lifestyle modification services under the 2017 ACC/AHA Hypertension Guideline. *J Clin Hypertens.* 2018;1377-1391. <https://doi.org/10.1111/jch.13364>


Hypertension in the NY State Community Health Centers*

UDS Data Five-Year Summary

Age and Race/Ethnicity	Patient Characteristics	Services	Clinical Data	Cost Data					
Clinical Data				2020	2021	2022	2023	2024	
Controlling High Blood Pressure *				60.46%	62.56%	66.40%	67.85%	69.74%	

- Overall, within NY adults with HTN treated in participating centers (1.3 million adults); **HTN control is ~70%**
- This estimate does not account for people without healthcare access or not accessing their care
- As we will see later in this webinar, **HTN control around 65% is typical for health systems where the system and clinicians are working toward a goal BP <140/90 mmHg**

CPCI HTN Control Rates




US hypertension guidelines

- **Up til 2003:** Guidelines issued by US government bodies until 2012, then
- **2012:** controversial JNC8 guideline, confusion among clinicians and health system managers. Subsequently guidelines taken over by American College of Cardiology/American Heart Association (ACC/AHA)
- **2015 SPRINT trial:** value of intensive vs standard treatment (goal <120 vs <140)
- **2017 ACC/AHA guideline** recommends *lower diagnostic threshold and intensive treatment goals*
- **Low adoption of 2012 guideline and wait until 2017 for ACC/AHA guideline meant that 2003 JNC7 guidelines were mainstay for 14 years**—the JNC7 "140/90" for most patients firmly entrenched in clinical practice, performance metrics, and value-based reimbursement schemes
- **Adoption of 2017 guideline slow at national level**—lower, 2017 guideline BP thresholds considered but not adopted by NCQA in 2025
- **September 2025:** release of 2025 ACC/AHA hypertension guideline

Implementing the 2025 HTN guidelines in practice, reaching 100% HTN control

- Guidelines only save lives if they are successfully implemented and scaled!
- [AMA MAP quality improvement tools](#)
- WHO HEARTS—similar
 - Simple HTN treatment protocols
 - Team-based care
 - Data & dashboards for monitoring/QI
- **Success stories, population level:** Hypertension Canada, South Korea HTN initiative—over ~60% population-level control (<140/90)
- **Success stories, health systems:** Kaiser System, VA, (>90% at <140/90) San Francisco safety net clinics (>70% at <140/90)*

*Fontil, V., Et al, Circ CVQO 2018



AMA MAP™ HTN Metrics

Measures

Measures	Hypertension Monitoring
	AMA MAP BP - HTN-Repeat Blood Pressure Measurement
	AMA MAP BP - Uncontrolled HTN Follow-Up
	AMA MAP Confirm BP
	AMA MAP Follow-up
Measures	Hypertension Prescribing
	Adult HTN Guideline Recommended Therapy
	AMA MAP BP - HTN-Medication Intensification
	AMA MAP BP - SBP Change After Med. Intensification
	AMA MAP Med Intens.
	AMA MAP SBP Reduction
	Combination Product Rx
	HTN >=140/90 and No Medication
	HTN <=140/90 on Monotherapy

Scorecards

Reports	Dental
	Diabetes
	HIV
	HTN
	AMA MAP BP Metrics
Reports	AMA MAP™ HTN
	AMA MAP™ HTN Prescribing
Reports	Hypertension Control
	Care Effectiveness
Reports	AMA MAP Blood Pressure Care Effectiveness Patients
	AMA MAP Blood Pressure Care Effectiveness Report
Reports	Behavioral Health Care Effectiveness Patients
	Behavioral Health Care Effectiveness Report
Reports	Diabetes Care Effectiveness Patients
	Diabetes Care Effectiveness Report

Dashboards

LIBRARY	UDS
	PVP
	Azara
	AMA MAP BP Metrics
	AMA MAP™ Hypertension
Reports	Cancer Screening
	Data Health - Lab Volume
	Data Health - Questionable Values
	Diabetes
	Panel Management
	Patient Risk Stratification
	Point of Care Alert Closure
	Predominant Conditions
	Referral Management
	Social Needs All Patients
	Social Needs Assessed

AMA MAP™ HTN Targets

AMA MAP™ HTN Recommended Targets

Target Administration 

Search Targets.. 

Updated AMA MAP HTN Targets



NAME	MEASURE	PRIMARY TARGET	SECONDARY TARGET	Actions
AMA MAP HTN	Hypertension Controlling High Blood Pressure (CMS 165v13)	70%	60%	
AMA MAP HTN	AMA MAP™ SBP Reduction After Med Intensification	70%	60%	
AMA MAP HTN	AMA MAP™ Med Intensification for Uncontrolled HTN	30%	20%	
AMA MAP HTN	AMA MAP™ Follow-up for SBP >140 or DBP >90	50%	40%	
AMA MAP HTN	AMA MAP™ Confirmatory BP Measurement In-Clinic	70%	60%	

2025 ACC/AHA Guidelines

-highlights for clinicians

-translation into practice

Five* take-aways, 2025 hypertension guidelines




- 1. Hypertension treatment prevents dementia!**
- 2. Revised HTN treatment groups**
- 3. Risk based-treatment of stage 1 HTN using
*AHA PREVENT score***
- 4. HTN management recommendations**
 - 4a: Stage 2 hypertension
 - 4b: Stage 1 hypertension with low risk
- 5. Team-based care recommended**

**Home BP monitoring recommendation—NOT covered in this webinar, to be covered in subsequent webinar...*

1. Hypertension treatment prevents heart disease, strokes...and dementia

- **Dementia is a disabling and costly condition, costing the U.S, \$345 billion annually**
- **No effective treatment**
- **But there is a way to prevent dementia—hypertension treatment!**
- ACC/AHA 2025 Hypertension guideline "recommends early treatment for people diagnosed with high blood pressure with a goal of systolic blood pressure...goal of <130 mm Hg for adults with high blood pressure to prevent cognitive impairment and dementia"
- ***People care about avoiding dementia! Need to find ways to communicate with patients***




2. HTN categories (same as 2017)

- 2025 Hypertension Categories

Blood Pressure Category	SBP	DBP
Normal	< 120 mmHg	and
Elevated	120 to 129 mmHg	and
Hypertension		
Stage 1 Hypertension	130 to 139 mmHg	or
Stage 2 Hypertension	≥ 140 mmHg	or
		≥ 90 mmHg


2. Revised treatment groups

- 2025 treatment indications and BP goals




Lower BP threshold & targets

- Setting diagnosis threshold at $\geq 130/80$ **increased treatment eligible population by ~5 million people** (2017 guideline; 2025 guideline will increase treatment-indicated by another 2 million...)
- **Greatest prevention benefit in treating high CVD risk stage 2 HTN (baseline $\geq 140/90$) to intensive goal ($< 130/80$)***



Lower average BP: key to 100% control (to <140/90)

- AMA MAP program health system data and SPRINT trial
- mSBP = mean systolic blood pressure (mean = average)



Going Beyond the Gap List


In order to achieve 100% blood pressure control, we need to tailor our workflows to align with these new standards.

But how?

UDS 2024 CQMs

FULL REPORT >

MEASURE	RESULTS
Childhood Immunization Status (CMS 117v12)	76.1%
Child Weight Assessment / Counseling for Nutrition / Physical Activity (CMS 155v12)	46.2%
BMI Screening and Follow-Up 18+ Years (CMS 69v12)	52.0%
Depression Remission at Twelve Months (CMS 159v12)	39.1%
Screening for Depression and Follow-Up Plan (CMS 2v13)	
Tobacco Use: Screening and Cessation (CMS 138v12)	
Colorectal Cancer Screening (CMS 130v12)	
Cervical Cancer Screening (CMS 124v12)	
Breast Cancer Screening Ages 50-74 (CMS 125v12)	
Hypertension Controlling High Blood Pressure (CMS165v12)	



Let's Explore!



TY September 2025

Center Overview

TY September 2025

4,900 PATIENTS

41,537 VISITS

Events & Announcements

EVENT NEW

October Webinars
Join us for our October webinars! Back to Basic...

a SEP 12

ANNOUNCEMENT NEW

We're Listening:
Share Your Feedback for a Chance to Win \$150
Your Opinion Matters!
Take the Client ...

a SEP 09

ANNOUNCEMENT

What's New in DRVS? August
What's New in DRVS?
New features and ...

a SEP 08

ANNOUNCEMENT

UDS Table 6b Updates Released

Prompting Providers at the Point of Care

6:53 AM Tuesday, November 14, 2023

Visit Reason: **Office visit Departure**

Wilcher, Talitha

MRN: 1103221

DOB: 2/6/1943 (80)

Phone: 508-443-3742

Lang: Arabic

Risk: **Low (30)**

Portal Access: Y

Cohorts: Adults Sys > 110, Clinical Pharmacy

PCP: Black, Ronda

Payer: Medicare

CM: Eric Gunther

DIAGNOSES (7)

ASCVD	Cancer	Depression
HCV	HIV	HTN-NE
IVD		

RISK FACTORS (7)

ANTICOAG	Chronic Opioid Tx	IDD
MSM	Pre-DM	SMI
TOB		

EMPLOYMENT	HOMELESS	LANGUAGE
MED/CARE	MIGRANT	RACE
STRESS	TRANSPORT-MED	UTILITY
VIOLENCE		

ALERT	MESSAGE	DATE	RESULT
LDL	Out of Range	1/17/2023	154
BP	Out of Range	1/17/2023	158/77

OPEN REFERRAL W/O RESULT	SPECIALIST/LOCATION	ORDERED DATE	APPT. DATE
Allergist	Samantha Frost / Brookline	1/17/2023	1/25/2023
Radiology	Samantha Frost / Burlington	1/17/2023	2/7/2023
Accupuncture	John Smith / Burlington	1/15/2023	2/4/2023

Configure Your Alerts

Edit

GENERAL **DATE CRITERIA** **RESULT CRITERIA** **POPULATION DEFINITION**

NUMERIC RESULTS
Observations can also be triggered by numeric data associated with the observation, such as a lab result or BP reading. For observations with multiple results, like BP, use the numeric 2 threshold field, otherwise leave it empty.

MESSAGE
Out of Range

ALERT IF **NUMERIC 1 THRESHOLD** **NUMERIC 2 THRESHOLD**

Numeric result >= 140 90

ALPHANUMERIC RESULTS
Alphanumeric observation results can trigger results as well. An alert will be triggered if the observation result is equal to the specified value.

MESSAGE **ALPHA VALUE**

Cancel Confirm

Edit

GENERAL **DATE CRITERIA** **RESULT CRITERIA** **POPULATION DEFINITION**

NUMERIC RESULTS
Observations can also be triggered by numeric data associated with the observation, such as a lab result or BP reading. For observations with multiple results, like BP, use the numeric 2 threshold field, otherwise leave it empty.

MESSAGE
Out of Range

ALERT IF **NUMERIC 1 THRESHOLD** **NUMERIC 2 THRESHOLD**

Numeric result >= 120 80

ALPHANUMERIC RESULTS
Alphanumeric observation results can trigger results as well. An alert will be triggered if the observation result is equal to the specified value.

MESSAGE **ALPHA VALUE**

Cancel Confirm

Other Alerts to Consider

Enable appropriate BP Alerts, assign alert owner, and update PVP name if needed

Alert Administration

Category	Name	PVP Name	Description	Owner	Created
Vitals	BP	BP	Alert will trigger if Most Recent Blood Pressure has not occurred in the last 1 years, or if numeric_1 value is >= 140 and numeric_2 value is >= 90. Alert only applies to patients <= 85 yrs old. Patient must have IVD or AMI or CABG or PCI or Hypertension or Diabetes.		02/09/2018
Vitals	BP Stage 1 Repeat	Blood Pressure Repeat Measurement	Alert will trigger for all patients where a Stage 1 or higher blood pressure (>=130/80) was recorded at the most recent visit with a blood pressure check where there was no repeat blood pressure recorded at that visit. This alert is not configurable		10/18/2023
Vitals	Elevated BP Stage 1 or 2	BP High Stage 1 or 2 No Dx	Alert will trigger for patients who had at least a Stage 1 or Stage 2 blood pressure reading in the last year with no record of an active diagnosis for essential hypertension, or other secondary hypertension diagnosis. This alert is not configurable		10/04/2023

Tracking BP Trends

Who are my patients coming in this week with HTN?

BLOOD PRESSURE		BP 2ND MOST RECENT		BP 3RD MOST RECENT		MOST RECENT BMI		CHOLESTEROL		TRIG		HDL			
VITALS DATE	VALUE	SYSTOLIC	DIASTOLIC	DATE	RESULT	DATE	RESULT	DATE	VALUE	DATE	CODE	RESULT	DATE	RESULT	DATE
8/28/2025	134/77	134	77	7/30/2025	150/77	6/17/2025	133/65	8/28/2025	31.16	3/17/2025	2093-3	186	3/17/2025	66	3/17/2025
8/12/2025	124/76	124	76	7/29/2025	124/80	6/3/2025	128/82	8/12/2025	28.72	7/29/2025	2093-3	190	7/29/2025	42	7/29/2025
5/16/2025	197/80	197	80	4/23/2025	169/85	4/16/2025	203/106	5/16/2025	16.64	7/15/2024	2093-3	131	7/15/2024	63	7/15/2024
8/18/2025	131/80	131	80	7/28/2025	133/83	4/24/2025	119/80	8/18/2025	30.41	7/28/2025	2093-3	197	7/28/2025	194	7/28/2025
9/2/2025	132/82	132	82	5/30/2025	148/87	5/16/2025	143/87	9/2/2025	39.25	5/16/2025	2093-3	198	5/16/2025	67	5/16/2025
9/2/2025	135/71	135	71	8/15/2025	153/63	7/15/2025	159/80	9/2/2025	28.89	1/30/2025	2093-3	149	1/30/2025	108	1/30/2025
7/24/2025	121/87	121	87	5/21/2025	146/103	5/13/2025	132/92	7/24/2025	30.56	9/26/2024	2093-3	139	9/26/2024	75	9/26/2024
8/26/2025	150/82	150	82	4/2/2025	134/81	2/4/2025	136/90	8/26/2025	28.41	8/26/2025	2093-3	225	8/26/2025	103	8/26/2025
6/11/2025	130/77	130	77	4/18/2025	132/70	3/24/2025	111/68	6/11/2025	23.17	2/20/2025	2093-3	160	2/20/2025	129	2/20/2025
7/17/2025	118/79	118	79	6/17/2025	125/77	4/16/2025	100/53	7/17/2025	31.27	11/27/2024	2093-3	145	11/27/2024	65	11/27/2024
8/19/2025	149/64	149	64	7/18/2025	117/50	7/15/2025	136/68	8/19/2025	26.85	12/7/2024	2093-3	158	12/7/2024	105	12/7/2024
8/25/2025	106/77	106	77	8/18/2025	117/79	8/5/2025	115/68	8/25/2025	27.80	12/16/2024	2093-3	128	12/16/2024	45	12/16/2024
8/12/2025	150/79	150	79	6/20/2025	133/76	5/13/2025	153/84	8/12/2025	37.20	6/20/2025	2093-3	178	6/20/2025	107	6/20/2025
9/8/2025	136/96	136		8/15/2024	126/85	7/9/2024	128/85	9/8/2025	36.04	8/15/2022	2093-3	173	8/15/2022	131	8/15/2022
8/26/2025	122/74							7/26/2025	32.44	7/18/2024	2093-3	287	7/18/2024	213	7/18/2024

And how have their blood pressures been trending over their last three visits?

Tracking BP Trends

AMA MAP Hypertension Care Effectiveness Patients REPORT

DATE RANGE 09/22/2025-09/26/2025 RENDERING PROVIDERS All Rendering Provid... PATIENT DIAGNOSES All Patient Diagnoses SERVICE LINES All Service Lines FILTER + Add Filter Update

Overview - Population: Dyn - OOC Blood Pressure

BLOOD PRESSURE CONTROL (BP)

● Stage 2 Severe (>=160 or >=100)	282
● Stage 2 HTN (140-159 or 90-99)	1,113
● Stage 1 HTN (130-139 or 80-89)	1,000
● Elevated BP (120-129 and <80)	304
● Normal (<120/80)	298
● No Score	6

137.0 AVG SYSTOLIC BLOOD PRESSURE ▼ -2.6 Last 12 mths.

981 SYS BP PTS WITH A >=10 MM/HG DROP

1.8 AVG Class Count ▲ 0.1 Last 12 mths.

3,003 PATIENTS

ANTIHYPERTENSIVE MEDICATION CLASS COUNT

● >5	2
● 4-5	142
● 3	342
● 2	581
● 1	689
● 0	1,247

Search Patients ... Reset Columns SAVED COLUMNS

BP CONTROL STATUS


BP CONTROL STATUS	FIRST SYSTOLIC BP IN LAST 12 MTHS	FIRST DIASTOLIC BP IN LAST 12 MTHS	MOST RECENT SYSTOLIC BP LAST 12 MTHS	MOST RECENT DIASTOLIC BP LAST 12 MTHS	FIRST ANTIHTN MED COUNT LAST 12 MTHS	
BP CONTROL STATUS	DATE	RESULT	DATE	RESULT	CHANGE	DATE
ELEVATED BP	135		126	126	▼ -9	5/23/2025
NORMAL	136		130	130	▼ -6	6/11/2025
No Score	128		133	133	▲ 5	8/22/2025
STAGE 1 HTN	127		143	143	▲ 1	7/23/2025
STAGE 2 HTN	129		154	154	▼ -19	7/7/2025
STAGE 2 SEVERE	129		110	110	▼ -19	7/2/2025
	133	9/13/2024	69	7/1/2025		77
	132	11/4/2024	89	3/18/2025		71
	153	11/4/2024	66	8/25/2025		90
	122	11/11/2024	68	5/12/2025		74
	144	9/18/2024	98	7/23/2025		2.0
	128	10/17/2024	81	8/15/2025		11/4/2024
			128	128	0	79
						2.0
						9/18/2024
						11/12/2024

Easily identify patients with different levels of HTN


Easily identify patients with increasing systolic BP in the last 12 months

Demo Data


Don't just evaluate the outcomes, evaluate your process!




Process Metrics | Collecting BP Every Visit




Process Metrics | Collecting Confirmatory BP



Process Metrics | Scheduling Follow Up Visits




Which providers are routinely scheduling follow up visits after patients are identified with uncontrolled BP?



3. CVD risk-based patient selection

- For all patients with stage 1 HTN (130-139/80-89), risk-based approach




CVD risk-based patient selection: AHA PREVENT score

AHA PREVENT score (2024) has 3 advantages over prior "pooled cohorts equations" for assessing 10-year CVD risk:

1. PREVENT is based on more contemporary data; cohort and health system data—leading to more accurate risk assessment in today's adults
2. Just as good at ranking patients from high to low risk—for patient selection for treatment
3. CVD is more than "atherosclerotic CVD" (ASCVD)—PREVENT CVD equation includes hemorrhagic stroke and heart failure outcomes. More appropriate for hypertension-related risk assessment

AHA PREVENT Score—core set and expanded risk factors



DRV'S & AHA PREVENT Alignment | Custom Registry

AHA PREVENT Components:

- Age
- Sex
- Total Cholesterol
- HDL Cholesterol
- SBP
- BMI
- eGFR
- Diabetes Dx
- Smoking Status
- Anti-Hypertensive Medication
- Lipid-Lowering Medication

Optional Components:

- UACR
- HbA1C
- Zip Code (social deprivation)

Edit

X

GENERAL	POPULATION DEFINITION	DATA ELEMENTS
Select from the options below, double click to add from the left or double click from the right to remove.		
TITLE next app	CATEGORIES All Claim Demographics Dental Diabetes Diagnosis Encounter Immunization Immunizations Incarceration	OPTIONS Next Appointment Time Next Appointment Type
		SELECTED BMI Estimated Glomerular Filtration Rate (eGFR) Result Diabetes Smoking Status Anti-Hypertensive Pharmacologic Therapy Statin UACR Result A1c SDOH Triggers Next Appointment Qualifying Encounter

Cancel

Confirm

AHA PREVENT | Custom Registry

AHA PREVENT Risk Registry   JUST AMELIA.FOX@AZARAHEALTHCARE.COM

VISIT DATE RANGE: 09/16/2024-09/16/2025  RENDERING PROVIDERS: All Rendering Provid...  PERIOD TENSE: No Match 

 FILTER   VALUE SETS  + Add Filter  Update

 **REGISTRY**

Search Patients...   Reset Columns  SAVED COLUMNS 

CHOLESTEROL				HDL		BLOOD PRESSURE				MOST RECENT BMI		EGFR				DIABETES DX	
AGE	DATE	CODE	RESULT	DATE	RESULT	VITALS DATE	VALUE	SYSTOLIC	DIASTOLIC	DATE	VALUE	DATE	CODE	RESULT	DATE	CODE	
47	2/25/2025	2093-3	206	2/25/2025	43.00	7/11/2025	150/100	150	100	7/11/2025	37.40	5/30/2025	98979-8	111	2/20/2025	E11.65	
72	9/12/2025	2093-3	221	9/12/2025	36.00	8/25/2025	115/78	115	78	8/25/2025	32.20	9/12/2025	98979-8	52			
51	2/4/2025	2093-3	183	2/4/2025	37.00	1/8/2025	150/82	150	82	1/8/2025	43.00	2/4/2025	50210-4	104.20			
65						8/4/2025	138/88	138	88	8/4/2025	22.30	11/2/2024	50210-4	82.40			
75										4/18/2025	26.90						
55	3/1/2025	2093-3	194	3/1/2025	62.00	2/26/2025	122/86	122	86	2/26/2025	26.50	3/1/2025	98979-8	75.00	1/31/2024	E11.9	
54																	
42																	
33	1/29/2025	2093-3	185	1/29/2025	41.00	9/8/2025	120/80	120	80	9/8/2025	38.60	5/12/2025	98979-8	117.00			
37	12/13/2024	2093-3	175	12/13/2024	41.00	12/13/2024	120/80	128	84	12/13/2024	20.50	12/13/2024	98979-8	108.00			
69										3/14/2025	35.90						
32	10/15/2024	2093-3	175	10/15/2024	41.00	10/15/2024	120/80	121	78	4/9/2025	33.80	3/21/2025	98979-8	85.00			
42	4/3/2025	2093-3	214	6/19/2025	81.00	6/11/2025	142/82	142	82	6/11/2025	24.20	3/25/2025	98979-8	82.00			
60																	
62	6/11/2024	2093-3	214	6/19/2025	81.00	6/11/2025	142/82	120	70	9/3/2025	22.60	6/11/2024	98979-8	99.00			
65	4/15/2025	2093-3	214	6/19/2025	81.00	6/11/2025	142/82	145	76	4/15/2025	24.20	3/25/2025	98979-8	82.00			
50	6/19/2025	2093-3	214	6/19/2025	81.00	6/11/2025	142/82	142	82	6/11/2025	31.30	6/19/2025	50210-4	99.00			

1 to 17 of 12,281  Page 1 of 723 

 **Demo Data**

AHA PREVENT | Custom Registry

AHA PREVENT Risk Registry   JUST AMELIA.FOX@AZARAHEALTHCARE.COM

VISIT DATE RANGE RENDERING PROVIDERS PERIOD TENSE

09/16/2024-09/16/2025 All Rendering Provid... No Match

FILTER  Add Filter  Update 

REGISTRY  VALUE SETS 

Search Patients ...  Reset Columns  SAVED COLUMNS 

CHOLESTEROL				HDL		BLOOD PRESSURE				MOST RECENT BMI			EGFR			DIABETES DX		
AGE	DATE	CODE	RESULT	Greater than or equals		VITALS DATE	VALUE	SYSTOLIC	DIASTOLIC	DATE	VALUE	DATE	CODE	RESULT	DATE	CO...		
47	2/25/2025	2093-3		200		7/11/2025	150/100	150	100	7/11/2025	37.40	5/30/2025	98979-8	111	2/20/2025	E11.65		
72	9/12/2025	2093-3		200		8/25/2025	115/78	115	78	8/25/2025	32.20	9/12/2025	98979-8	52				
62	6/11/2024	2093-3		200		9/3/2025	120/70	120	70	9/3/2025	22.60	6/11/2024	98979-8	99.00				
65	4/15/2025	2093-3		200		4/15/2025	145/76	145	76	4/15/2025	24.20	3/25/2025	98979-8	82.00				
50	6/19/2025	2093-3		200		6/11/2025	142/82	142	82	6/11/2025	31.30	6/19/2025	50210-4	99.00				
43	10/25/2024	2093-3		224	10/25/2024	10/25/2024	154/108	154	108	10/25/2024	46.40	10/25/2024	98979-8	77.00				
47	2/13/2024	2093-3		220	2/13/2024	35.00	2/13/2025	143/90	143	90	4/30/2025	29.80	2/13/2024	62238-1	68.00	2/13/2024	E11.65	
71	2/19/2025	2093-3		218	2/19/2025	2/19/2025	72	8/5/2025	37.20	2/19/2025	98979-8	69.00	12/19/2023	E11.9				
48	2/4/2025	2093-3		210	2/4/2025	2/4/2025	72	2/4/2025	22.20	2/4/2025	98979-8	93.00						
61	3/14/2025	2093-3		206	3/14/2025	3/14/2025	72	6/10/2025	24.10	3/14/2025	98979-8	73.00						
44	12/28/2023	2093-3		202	12/28/2023	12/28/2023	74	6/5/2025	21.90	2/23/2025	98979-8	90.00						
49	7/31/2025	2093-3		218	7/31/2025	7/31/2025	70	9/9/2025	25.20	7/31/2025	98979-8	96.00						
40	6/13/2024	2093-3		245	6/13/2024	6/13/2024	70	9/9/2024	16.30	6/13/2024	98979-8	96.00						
42	12/29/2023	2093-3		204	12/29/2023	12/29/2023	70	5/28/2025	32.70	4/10/2024	98979-8	101.00	8/12/2024	E11.9				
75	12/21/2023	2093-3		208	12/21/2023	46.00	7/22/2025	130/74	130	74	7/22/2025	28.00	4/8/2025	50210-4	80.40			
47	5/23/2025	2093-3		217	5/23/2025	66.00	8/1/2025	120/80	120	80	8/1/2025	23.20	7/23/2025	50210-4	85.40			
53	1/12/2024	2093-3		297	1/12/2024	72.00	5/29/2025	150/100	150	100	6/12/2025	22.90	1/2/2025	50210-4	59.00			

1 to 17 of 2,140  Page 1 of 126 

Who are my patients with a Cholesterol level higher than 200

azara healthcare

AHA PREVENT | Custom Registry

AHA PREVENT Risk Registry   JUSTAMELIA.FOX@AZARAHEALTHCARE.COM

VISIT DATE RANGE RENDERING PROVIDERS PERIOD TENSE

09/16/2024-09/16/2025 All Rendering Provid... No Match + Add Filter Update

REGISTRY  VALUE SETS

Search Patients ... 

Reset Columns SAVED COLUMNS 

CHOLESTEROL				HDL		BLOOD PRESSURE			MOST RECENT BMI			EGFR			DIABETES DX	
AGE	DATE	CODE	RESULT	DATE	RESULT	VITALS DATE	VALUE	SYSTOLIC	STRETCH	STRETCH	STRETCH	STRETCH	STRETCH	STRETCH	STRETCH	STRETCH
47	2/25/2025	2093-3	206	2/25/2025	43.00	7/11/2025	150/100									
65	4/15/2025	2093-3	218	4/15/2025	90.00	4/15/2025	145/76									
50	6/19/2025	2093-3	214	6/19/2025	81.00	6/11/2025	142/82									
43	10/25/2024	2093-3	224	10/25/2024	50.00	10/25/2024	154/108									
47	2/13/2024	2093-3	220	2/13/2024	35.00	4/30/2025	143/90									
71	2/19/2025	2093-3	218	2/19/2025	62.00	8/5/2025	150/72									
61	3/14/2025	2093-3	206	3/14/2025	73.00	6/10/2025	130/86									
44	12/28/2023	2093-3	202	12/28/2023	74.00	6/5/2025	130/94									
40	6/13/2024	2093-3	245	6/13/2024	80.00	9/9/2024	138/86									
75	12/21/2023	2093-3	208	12/21/2023	46.00	7/22/2025	130/74									
53	1/12/2024	2093-3	297	1/12/2024	72.00	5/29/2025	150/100									
53	3/17/2025	2093-3	204	3/17/2025	51.00	5/8/2025	140/90									
66	3/19/2024	2093-3	267	3/19/2024	45.00	4/2/2024	194/83									
49	1/24/2025	2093-3	214	1/24/2025	38.00	9/12/2025	145/90									
43	2/3/2025	2093-3	262	2/3/2025	49.00	9/2/2025	130/81									
36	10/1/2024	2093-3	220	10/1/2024	64.00	9/9/2025	152/88									
67	9/3/2025	2093-3	206	9/3/2025	56.00	9/3/2025	137/81									

1 to 17 of 1,005 

And a systolic BP higher than 130

azara healthcare

AHA PREVENT | Custom Registry

AHA PREVENT Risk Registry
REGISTRY <JUST AMELIA.FOX@AZARAHEALTHCARE.COM>

VISIT DATE RANGE: 09/16/2024-09/16/2025 | RENDERING PROVIDERS: All Rendering Provid... | PERIOD TENSE: No Match | FILTER | Update

REGISTRY | VALUE SETS

Search Patients: SEARCH

Reset Columns | SAVED COLUMNS

HDL			BLOOD PRESSURE				MOST RECENT BMI			EGFR			DIABETES DX			SMOKING STATUS		ANTI-HTN MED	
ESU...	DATE	RESULT	VITALS DATE	VALUE	SYSTOLIC	DIASTOLIC	DATE	VALUE	DATE	CODE	RESULT	DATE	CO...	SEARCH...	DATE	NAME			
206	2/25/2025	43.00	7/11/2025	150/100	150	100	7/11/2025	37.40	5/30/2025	98979-8	111	2/20/2025	E11.65	(Select All)	8/2024	fu			
220	2/13/2024	35.00	4/30/2025	143/90	143	90	4/30/2025	29.80	2/13/2024	62238-1	68.00	2/13/2024	E11.65	(Blanks)	7/2025	an			
218	2/19/2025	62.00	8/5/2025	150/72	150	72	8/5/2025	37.20	2/19/2025	98979-8	69.00	12/19/2023	E11.9	<input checked="" type="checkbox"/> 237599002	8/2025	hr			
220	7/1/2025	42.00	8/25/2025	140/60	140	60	8/25/2025	40.00	7/1/2025	98979-8	78.00	2/12/2025	4405400	<input checked="" type="checkbox"/> 313436004	25/2025	an			
228	5/14/2025	36.00	5/8/2025	136/70	136	70	5/8/2025	26.90	5/14/2025	98979-8	111.00	5/8/2025	E11.65	<input checked="" type="checkbox"/> 421326000	5/2025	vi			
213	8/5/2025	49.00	8/11/2025	150/90	150	90	8/11/2025	43.20	8/5/2025	98979-8	56.00	8/11/2025	E11.9		17/2025	li			
200	3/18/2025	55.00	3/18/2025	138/78	138	78	3/18/2025	36.40	3/18/2025	98979-8	81.00	3/5/2024	E11.9		22/2025	lo			
253	8/22/2025	42.00	8/22/2025	140/82	140	82	8/22/2025	29.80	8/22/2025	98979-8	122.00	8/27/2025	E11.65						
233	9/4/2024	46.00	3/17/2025	130/68	130	68	3/17/2025	31.00	9/4/2024	50210-4									
353	11/22/2024	49.00	3/31/2025	132/90	132	90	3/31/2025	39.90	11/22/2024	98979-8									
243	4/10/2025	45.00	9/25/2024	145/70	145	70	9/25/2024	17.20	4/24/2025	98979-8									
228	1/7/2025	46.00	7/9/2025	134/86	134	86	7/9/2025	46.70	1/7/2025	98979-8	87.00	1/8/2025	E11.65						
205	4/29/2025	33.00	8/22/2025	150/90	150	90	8/22/2025	32.40	7/23/2025	50210-4	106.00	1/23/2025	E11.65	<input type="checkbox"/> 4/20/2022	R	5/20/2025			
239	9/10/2025	47.00	9/12/2025	138/85	138	85	9/12/2025	36.10	9/10/2025	98979-8	111.00	9/12/2025	E11.42	<input type="checkbox"/> 2/11/2021	Y				
253	5/6/2025	28.00	6/17/2025	133/68	133	68	6/17/2025	39.50	5/6/2025	98979-8	69.00	10/6/2021	E11.40	<input type="checkbox"/> 1/6/2022	R	9/3/2025			
220	12/31/2024	53.00	4/7/2025	131/89	131	89	4/7/2025	26.80	12/31/2024	98979-8	68.00	12/20/2021	E11.65	<input type="checkbox"/> 3/21/2022	N				
241	8/12/2025	55.00	8/12/2025	149/79	149	79	8/12/2025	25.20	8/12/2025	98979-8	92.00	10/22/2021	E11.9						

1 to 17 of 161

And a diagnosis of Diabetes

AZARA healthcare

AHA PREVENT | Custom Registry

AHA PREVENT Risk Registry   JUST.AMELIA.FOX@AZARAEALTHCARE.COM

VISIT DATE RANGE  RENDERING PROVIDERS PERIOD TENSE

09/16/2024-09/16/2025 All Rendering Provid... No Match   

 **REGISTRY**  **VALUE SETS**

Search Patients...   

		DIABETES DX		SMOKING STATUS		ANTI-HTN MED		STATIN MED		UACR		A1C OR GM			
CODE	RESULT	DATE	CO.  V	DATE	DETAIL	DATE	NAME  V	Search...	NAME  V	DATE	CODE	RESULT	VALUE	DATE	
98979-8	111.00	5/8/2025	E11.65					(Select All)		5/14/2025	9318-7	<30 mg/g	7.00	5/14/2025	
50210-4	116.30	3/18/2025	E11.9					(Blanks)	rosuvastatin 10 mg tablet					9/4/2024	
98979-8	94.00	1/1/2025	E11.69					amlodipine 10 mg tablet	atorvastatin 20 mg tablet					11/22/2024	
98979-8	39.00	8/13/2024	E11.319					amlodipine 5 mg tablet						4/10/2025	
98979-8	111.00	9/12/2025	E11.42	2/11/2021	Y			amlodipine 5 mg-valsartan 160 mg ta	atorvastatin 40 mg tablet					9/10/2025	
98979-8	68.00	12/20/2021	E11.65	3/21/2022	N				rosuvastatin 5 mg tablet	12/31/2024	9318-7	<30 mg/g	6.10	4/7/2025	
50210-4	92.00	11/18/2024	E11.65						simvastatin 20 mg tablet					6/2/2025	
50210-4	74.50	6/19/2018	E10.3299						rosuvastatin 5 mg tablet	11/5/2024	14959-1	<30 mg/g	6.00	6/3/2025	
50210-4	129.70	5/4/2022	E11.65							6/16/2023	14959-1	<30 mg/g	5.60	5/27/2025	
98979-8	98.00	6/16/2025	E11.9						0 mg tablet					6/11/2025	
98979-8	96.00	4/1/2025	E11.9						0 mg tablet					4/29/2025	
98979-8	95.00	2/5/2025	E11.42						0 mg tablet	2/5/2025	30000-4	<30 mg/g	8.90	6/30/2025	
50210-4	91.90	7/23/2025	E11.9					10/27/2024	617312	atorvastatin 10 mg tablet	2/8/2024	14959-1	<30 mg/g	6.40	9/2/2025
98979-8	87.00	4/4/2025	E11.9					1/9/2025	859424	rosuvastatin 5 mg tablet					7/11/2025
50210-4	115.60	10/28/2024	E11.9					3/14/2025	617312	atorvastatin 10 mg tablet					6/3/2025
98979-8	98.00	8/7/2025	E11.9	11/15/2020	R			8/25/2025	617310	atorvastatin 20 mg tablet	8/7/2025	30000-4	<30 mg/g	5.80	8/26/2025
98979-8	106.00	9/25/2020	E11.65	11/17/2021	Y			7/15/2025	859751	rosuvastatin 20 mg tablet					7/15/2025

1 to 17 of 30 

Who are NOT prescribed a hypertension medication

AHA PREVENT | Custom Registry

AHA PREVENT Risk Registry   

REGISTRY  VALUE SETS  FILTER  

VISIT DATE RANGE: 09/16/2024-09/16/2025  RENDERING PROVIDERS: All Rendering Provid...  PERIOD TENSE: No Match   

REGISTRY    

		DIABETES DX		SMOKING STATUS		ANTI-HTN MED		STATIN MED		UACR		A1C OR GM		
CODE	RESULT	DATE	CO...	DATE	DETAIL	DATE	NAME	START DATE	RXNORM	NAME	RESULT	VALUE	DATE	
98979-8	111.00	5/8/2025	E11.65								0 mg/g	7.00	5/14/2025	
98979-8	39.00	8/13/2024	E11.319								0 mg/g	5.60	5/27/2025	
50210-4	129.70	5/4/2022	E11.65								atovastatin 10 mg tablet	<300 mg/g	95.70	7/2/2025
98979-8	99.00	8/29/2024	E11.69								atovastatin 20 mg tablet	<30 mg/g	19.00	8/29/2025
98979-8	86.00	10/5/2023	E11.9								atovastatin 40 mg tablet	<30 mg/g	3.33	5/28/2025
98979-8	82.00	10/1/2018	E11.9								atorvastatin 20 mg tablet	<30 mg/g	6.60	8/7/2025
98979-8	102.00	8/7/2025	E11.69								atorvastatin 40 mg tablet	<30 mg/g	1/29/2025	
50210-4	65.70	3/1/2024	313436004								atorvastatin 20 mg tablet	<30 mg/g	8/26/2025	
98979-8	77.00	3/16/2025	E11.319								atorvastatin 40 mg tablet	<30 mg/g	4/8/2024	
98979-8	77.00	1/6/2025	E11.9	1/25/2022	R						atorvastatin 20 mg tablet	<30 mg/g	6/16/2025	
98979-8	60.00	6/10/2025	E11.69								atorvastatin 40 mg tablet	<30 mg/g	4.00	6/9/2025
98979-8	88.00	11/10/2021	E11.9								atorvastatin 20 mg tablet	<30 mg/g		

Or a statin medication

1 to 12 of 12 

AHA PREVENT | Custom Registry

AHA PREVENT Risk Registry   JUST AMELIA.FOX@AZARAHEALTHCARE.COM

FILTER  

VISIT DATE RANGE: 09/16/2024-09/16/2025  RENDERING PROVIDERS: All Rendering Provid...  PERIOD TENSE: No Match  + Add Filter 

REGISTRY  VALUE SETS  

A1C OR GMI										NEXT APPOINTMENT		MOST RECENT ENCOUNTER			
RESULT	VALUE	DATE	CODE	RESULT	NUMERIC RESULT	TRIGGERS	TALLY	DATE		No Date			DATE	PROVIDER	LOCATION
<30 mg/g	7.00	5/14/2025	4548-4	7.9		7.90		0		No Date					
		4/10/2025	4548-4	8.0		8.00	RACE LANGUAGE	2							
<30 mg/g	5.60	5/27/2025	4548-4	8.7		8.70	RACE	1							
<30 mg/g	3.33	5/28/2025	4548-4	6.3		6.30	FPL<200%	1							
		8/26/2025	4548-4	6.1		6.10	RACE	1							
		6/16/2025	4548-4	6.1		6.10		0							
<30 mg/g	4.00	6/9/2025	4548-4	6.7		6.70		0							

AND do not have an upcoming appointment



Let's call and schedule these patients in for visits!

Custom Registry Use Cases



Run for the day ahead for patients seeing a specific provider to proactively identify patients for elevated levels of engagement



Run for the last year to identify high-risk patients with social needs barriers for referral to care management services



Run for the week ahead to identify high-risk patients without anti-hypertensive and statin prescriptions and connect patients to clinical pharmacy





What else?

4a. Management of stage 2 HTN(>=140/90)

- Let's focus on management of Stage 2 HTN in the 2025 guideline



Stage 2: initial 2-drug combo



The evidence: dual combination meds for stage 2 HTN

Evidence: initial single pill dual drug combinations vs monotherapy

- Superior performance consistent across multiple RCTs
- Dual therapy vs monotherapy – initial dual drug treatment lowers mean systolic BP by >7.0 mmHg and improves hypertension control by >40%*

Dual	Trials/Pts.	Diff. in mean SBP & 95% CI			Trials/Pts.	Diff. in mean DBP & 95% CI			Trials/Pts.	RR for BP control & 95% CI		
<1+<1	13/2842	-2.8	(-4.0 to -1.6)	15/3151	-0.7	(-1.5 to 0.1)	7/1872	1.11	(0.92 to 1.34)			
1+<1	8/1679	-4.7	(-6.3 to -3.2)	10/3151	-2.8	(-3.3 to -2.3)	9/2724	1.25	(1.16 to 1.35)			
1+1	7/1938	-7.5	(-9.5 to -5.4)	8/1983	-4.5	(-5.3 to -3.6)	7/1825	1.42	(1.27 to 1.58)			
		-10.0	-5.0	0.0	-6.0	-3.0	0.0	0.5	1	2		
		Favours Dual			Favours Dual			Favours Mono			Favours Dual	

<1+<1=dual low dose; 1+<1= standard and low dose; 1+1= dual standard dose.
WDAE= withdrawal due to adverse event

Evaluate Your Prescribing Practices

AMA MAP™ HTN Prescribing Scorecard REPORT

PERIOD: TY August 2025 | RENDERING PROVIDERS: All Rendering Provid... | FILTER | Add Filter | Update

GROUPING: No Grouping | TARGETS: Primary (green), Secondary (yellow), Not Met (pink) | REPORT FORMAT: Scorecard

MEASURE	RESULT	TARGET	NUMERATOR	DENOMINATOR	EXCLUSIONS	GAP	TO TARGET
① Adults with HTN Prescribed a Guideline Recommended Therapy	65.1%	Not Set	2,336	3,590	292	1,254	
① Uncontrolled HTN Prescribed a Guideline Recommended Therapy	71.7%	Not Set	646	901	97	255	
Details			179	901	97	179	
			23	901	97	235	
			837	1,963	156	1,126	538
			1,853	5,003	485	3,150	649

Demo Data


DEMOCRAPHICS >

MRN	PATIENTID	NAME	SEX AT BIRTH	DATE OF BIRTH	MEDICAID-NUMBER	PROVIDER
1101162	196	Galanis, Leonel	M	5/29/1981	3918364	Decelles, La
1100705	2174	Hawkinson, Robert	M	6/30/1992	8175524	Bridgewater
1104603	2211	Sorrells, Moses	M	1/29/1967	5264057	Fritz, Renata
1104638	2246	Maroudas, Ariel	M	8/31/2007	4166789	Black, Ronda
1104208	3324	Schmidt, Rob	M	11/19/2003	4585460	Ryan, Frank
1101040	3386	Minnich, Ed	M	9/19/1944	2362672	Mejido, Dani
1104389	4625	Vandewerker, Davis	F	2/3/1972	4671576	Green, Leslie

1 to 7 of 63 | Page 1 of 9

DOWNLOAD

Prescribing Practices by Provider



Prescribing Practices by Provider

AMA MAP™ HTN Prescribing Scorecard REPORT

PERIOD: TY August 2025 | RENDERING PROVIDERS: Adult Providers | FILTER | Add Filter | Update

GROUPING: Provider - Rendering | TARGETS: Primary (Green), Secondary (Yellow), Not Met (Red)

REPORT FORMAT: CrossTab

Provider - Rendering	Adult HTN Guideline Recommended Therapy	Uncontrolled HTN Guideline Recommended Therapy	HTN >=140/90 AND NO MEDICATION	HTN >=140/90 ON MONOTHERAPY	AMA MAP SBP Reduction	AMA MAP Follow-up
	66.2%	73.9%	17.6%	21.8%	27.0%	27.4%
	73.3%	77.0%	18.0%	26.2%	50.0%	46.2%
	62.8%	72.6%	25.3%	18.9%	7%	44.5%
	50.7%	75.0%	18.8%	56.3%	6%	57.9%
	64.3%	75.0%	22.0%			39.2%
	65.0%	65.0%	23.6%			20.7%
	63.4%	67.1%	17.1%			45.9%
	61.9%	61.1%	27.8%			33.3%
	72.4%	85.6%	14.4%			44.0%
	68.8%	77.9%	5.8%			30.3%
	65.0%	72.2%	19.5%	36.1%	41.0%	42.4%
	65.2%	81.0%	9.5%	19.0%	20.0%	48.5%
	76.0%	78.6%	10.3%	23.0%	44.0%	24.3%

Provider B has highest SBP reduction rates and low rates of hypertensive patients w/o medication. What are their best practices / workflows?

Prompting Medication Intensification

6:38 AM Tuesday, March 26, 2024

Visit Reason: Injury Departure

Sankary, Fermin

MRN: 1101240

DOB: 9/15/1997 (26)

Phone: 351-149-

9059

Lang: Mandarin

Portal Access: N

Cohorts: High Risk w/HTN

PCP: Black, Ronda

Payer: BCBS

CM: Patrick

Crowley

DIAGNOSES (0)

RISK FACTORS (0)

FPL<200%

HISP/LAT

HOMELESS



LANGUAGE

RACE

ALERT

Hypertension Medication Intensification

MESSAGE

Missing

RESULT

MA

Tobacco Scr

Missing

MA

BMI & FU

Missing

Provider

I/P Encounter

Occurred

8/2/2023

RAF G

CATEGORY	NAME	PVP NAME	ENABLED	DESCRIPTION	OWNER
Vitals	HTN Med Intensification	Hypertension Medication Intensification	N	Alert will trigger for patients who had the most recent blood pressure reading greater than 130/80 in the last year with an active diagnosis of Essential Hypertension who do not have a record of a prescription for a new class of Anti-Hypertensive medication as defined as one that was not prescribed in the in the year prior to the last 12 months This alert is not configurable	III Columns

Demo Data

Proactively Identify Prescribing Gaps

AMA MAP BP™ - HTN-Medication Intensification MEASURE

PERIOD RENDERING PROVIDERS

TY August 2023 All Rendering Provid...

FILTER Update

MEASURE ANALYZER DETAIL LIST VALUE SETS

Search Patients ...

All Gaps Num Excl SAVED COLUMNS

DEMOGRAPHICS >		HTN					HTN MEDICATION INTENSIFICATION				
NAME	MRN	TYPE		REASON	DIAGNOSIS DATE	DIAGNOSIS	SBP	DBP	ENC DATE	PRESCRIPTION	DRUG CLASS
Terkelsen, Douglass	1100022	ate	Physical		2/25/2022	I10	158	87			
Pewitt, Royal	1102662	ate	High BP		6/13/2022	I10	148	79			
Flanagan, Celeste	1102594	ate	Mental Health and Counseling		10/2/2022	I10	141	94			
Loftin, Raul	1102624	ate	Sick Visit		3/8/2022	I10	165	93			
Fenny, Dario	1102376	ate	Annual Visit		12/17/2022	I10	165	97			
Fenny, Dario	1102376	ate	Annual Visit		12/17/2022	I10	139	99			
Betance, Luther	1103243	ate	High BP		12/6/2022	I10	141	82			
Helmers, Stefan	1103256	ate	Sick Visit		9/23/2022	I10	140	90			
Helmers, Stefan	1103256	ate	Sick Visit		9/23/2022	I10	167	85			
Carnero, Hershel	1103094	ate	Sick Visit		11/25/2021	I10	150	93			

1 to 10 of 32 Page 1 of 4 > >1

Outreach to these 32 patients and engage them in care and/or clinical pharmacy

Intensifying Services | Care Management Candidates

AMA MAP BP™ - HTN-Average Systolic BP Change After Medication Intensification ⓘ

MEASURE

PERIOD RENDERING PROVIDERS

TY February 2024 All Rendering Provid...

FILTER ⚙️ Update ⚙️

MEASURE ANALYZER DETAIL LIST VALUE SETS

Search Patients ...

All Gaps Num Excl

Reset Columns SAVED COLUMNS

BASE ENC				F/U			
BASE ENCOUNTER	SBP	LOCATION	PROVIDER	ENCOUNTER	SBP	LOCATIONS	PROVIDER
1/3/2023	151			10/18/2023	166		
2/2/2023	185			6/1/2023	140		
3/2/2023	159			5/18/2023	136		
4/6/2023	142			12/14/2023	162		

1 to 4 of 84

84 patients haven't experienced a change in BP after medication intensification. Are there other barriers at play? Could they benefit from care management services?

Page 1 of 21 > >>

Demo Data

azara healthcare

AMA Care Effectiveness Report

Who are my patients with Stage 1 or 2 HTN with 1) an out of range systolic BP that 2) has increased significantly in the last year, and 3) only has 0-1 anti-hypertensive medications prescribed?



Search Patients ... Reset Columns SAVED COLUMNS Columns

BP CONTROL STATUS		MOST RECENT SYSTOLIC BP LAST 12 MTHS			MOST RECENT ANTIHTN MED COUNT LAST 12 MONTHS			OOC BP FIRST ENCOUNTER		OOC BP MOST RECENT ENCOUNTER		OOC
BP CONTROL STATUS	DATE	RESULT	CHAN...	↑	RESULT	DATE	STAT...	BP	DATE	BP	STAT	LAST
●	1/16/2025	191	▲ 84		1.0	1/16/2025	●	191/82	1/16/2025	191/103	No SI	
●	2/3/2025	204	▲ 81		-1.0	2/3/2025	●	160/80	2/3/2025	204/98	Missi	
●	6/9/2025	214	▲ 81				●	214/89	6/9/2025	214/89	Missi	
●	8/12/2025	178	▲ 80		-1.0	8/12/2025	●	162/76	8/12/2025	178/83	Missi	
●	8/29/2025	155	▲ 71		1.0	8/29/2025	●	155/94	8/29/2025	155/94	Missi	
●	6/24/2025	188	▲ 71		1.0	6/24/2025	●	148/91	6/24/2025	188/104	Missi	
●	3/13/2025	151	▲ 65				●	151/87	3/13/2025	151/87	Missi	
●	11/19/2024	148	▲ 60				●	148/76	11/19/2024	148/76	Missi	
●	8/27/2025	166	▲ 60				●	159/78	8/27/2025	166/76	Missi	
●	2/4/2025	204	▲ 60		0.0	2/4/2025	●	6/4/2025	2/4/2025	204/85	Sched	
●	9/3/2025	183	▲ 59				●	144/71	2/4/2025	204/85	Sched	
●	7/14/2025	195	▲ 58				●	10/8/2024	10/8/2024	183/69	Missi	
●	3/3/2025	196	▲ 58		-3.0	3/3/2025	●	8/21/2025	8/21/2025	183/69	Missi	
●	1/17/2025	218	▲ 56		1.0	1/17/2025	●	158/76	9/3/2025	195/61	Missi	
●	8/30/2025	166	▲ 56				●	7/14/2025	7/14/2025	195/61	Missi	

4b. Management of Stage 1, low risk

- Now let's move to the Stage 1 patients with PREVENT risk <7.5%


No
↓

Initiate anti-hypertensive medications to lower BP if average SBP \geq 130 mm Hg or DBP \geq 80 mm Hg after 3-6 months of lifestyle intervention attempts

COR 1


Initial HTN management: stage 1, low risk

- For Stage 1, low risk, recommend a high potassium, low sodium (DASH + low sodium) diet and consider low-sodium/high potassium salt substitutes for 3-6 months
- Prior US Preventive Task Force analysis found that primary care based diet and exercise advice interventions lowered systolic BP by ~1.0 mmHg*
- This means most of these patients (unless they're right on the border of 130/80 threshold) will be recommended drug treatment at 6 months*



5. Implement team-based care

- **Evidence: team-based care led by non-physicians** lowers BP/achieves HTN control the best*
- **Nurses, clinical pharmacists, community health workers**
- **Divide, assign HTN control process tasks (see Figure)**
- **Task assignment may be limited by/dictated by local scope of practice regulations**



Team-Based Approach to Hypertension

Research has shown that team-based care in hypertension control can show a significant reduction in systolic and diastolic BP as well as a statistically significant increase in disease knowledge score pre- and post-intervention

Team-based Care Interventions

Facilitate communication and coordination of care support among various team members

Enhance the use of evidence-based guidelines by team members

Establish regular, structured follow-up mechanisms to monitor patients' progress and schedule additional visits as needed

Actively engage patients in their own care by providing them with education about blood pressure medication, adherence support, and tools and resources for self-management

Anand V. Team-Based Approach in Hypertension Management: A Quality Improvement Project. *J Nurs Care Qual.* 2024 Jan-Mar 01;39(1):76-83. doi: 10.1097/NCQ.0000000000000726. Epub 2023 Jun 2. PMID: 37267122; PMCID: PMC10655909.

Facilitating Team-Based Care | PVP

2:00 PM Wednesday, May 22, 2024

Visit Reason: AWV

LOWE, REBECCA

MRN: 123456

DOB: 10/10/1964 (59)

Phone: (123) 456-7891

Lang: English

Risk: Moderate (25)

Portal Access: Y

Cohorts: Clinical Pharmacy, Q1 2024 DM Cohort

PCP: Fox, Amelia

Payer: INDEPENDENT HEALTH

ASSOCIATION - ENCOMPASS 65
(MEDICARE REPLACEMENT HMO)

CM: Knapp, Emma

DIAGNOSES (3)

Anxiety HTN-E HyLip

RISK FACTORS (2)

ASCVD Intermediate (10.75) BMI

TRANSPORTATION - MED INSURANCE

RAF GAPS DIAGNOSIS CATEGORIES (1)

Morbid Obesity

ALERT	MESSAGE	DATE	RESULT	OWNER
Colon CA 45+	Missing			
Mammo	Missing			
A1c	Out of Range	3/25/2024	9.5 %	
HIV	Missing			
LDL	Out of Range	6/21/2023	157	
	Missing			CHW
BP	Out of Range	3/25/2024	157/84	
Flu - Seasonal	Missing			
Ctrl Sub	Missing			


OPEN REFERRAL W/O RESULT	SPECIALIST/LOCATION	ORDERED DATE	APPT. DATE
CONSULT RHEUMATOLOGIST REFERRAL	RHEUMATOLOGY WELLNESS CARE OF BURLINGTON / 2355 UNION RD, BURLINGTON		2/15/2024
CONSULT ENDOCRINOLOGY REFERRAL	BURLINGTON MEDICAL / 70 BLANCHARD RD, BURLINGTON		8/3/2023

Demo Data

HTN Activities by Role

Role	Activities
 Quality Team	<ul style="list-style-type: none">• Monitor practice, team, provider performance• Create cohorts based on focus for intensification, pharmacy intervention, care manager engagement• Track & visualize impact of quality improvement efforts
 Care Team	<ul style="list-style-type: none">• Review/discuss/manage patients with treatment inertia• Identify hypertension care needs at the point of care• Participate in Care Team huddles
 Care Manager	<ul style="list-style-type: none">• Actively oversee/manage patients with changes in medication (cohort)• Provide home BP monitoring instruction/teach back• Self management goal setting / care planning• Conduct SDOH screens• Provide education or enabling resources• Participate in Care Team huddles
 Care Coordinator	<ul style="list-style-type: none">• Identify & outreach to patients with undiagnosed hypertension, high risk ASCVD without treatment, hypertensive tobacco users, etc.
 CHW	<ul style="list-style-type: none">• Conduct social needs screens• Refer patients for social care needs• Monitor social needs screening rates for patients with HTN

Team-Based Care Workflow



Summing Up

2025 HTN guidelines: summing up

- **Spread the news, and motivate patients to take their daily medicines: HYPERTENSION TREATMENT PREVENTS DEMENTIA**
- **GO FOR IT!** Overcome inertia and treat BP <120 mmHg as long as no side effects or polypharmacy concerns. **Target mean systolic BP of 120** at provider and clinic levels
- **Ensure access to dual drug single pill combinations** in formularies, pharmacy shelves—for Stage 2 HTN patients
- **Implement and improvise on Team-Based HTN Care**
- **Advocate in Albany** to increase scope of practice for non-physician workers (PAs, NPs, clinical pharmacists, community health workers)



Thank you!

Andrew Moran

aem35@cumc.columbia.edu

Literature cited in this webinar

- Aggarwal R, Yeh RW, Joynt Maddox KE, Wadhera RK. Cardiovascular Risk Factor Prevalence, Treatment, and Control in US Adults Aged 20 to 44 Years, 2009 to March 2020. *JAMA*. 2023 Mar 21;329(11):899-909. doi: 10.1001/jama.2023.2307. PMID: 36871237; PMCID: PMC9986841.
- Penko JM, Bellows BK, Hennessy S, Kazi DS, Boylan R, Zhang Y, Coxson PG, Goldman L, Bibbins-Domingo K, Moran AE. Cost-Effectiveness of Hypertension Treatment According to 2017 American College of Cardiology and American Heart Association Guidelines. *Circ Cardiovasc Qual Outcomes*. 2025 Aug;18(8):e011872. doi: 10.1161/CIRCOUTCOMES.124.011872. Epub 2025 Aug 19. PMID: 40827400; PMCID: PMC12367062.
- Writing Committee Members*; Jones DW, et al. AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2025 Sep 16;152(11):e114-e218. doi: 10.1161/CIR.0000000000001356. Epub 2025 Aug 14. PMID: 40811497.
- Egan B, Sutherland SE, Martin B, Riesser B, Moran A, Rodgers A, Rakotz M. Does mean systolic blood pressure less than 130 mm Hg ensure high rates of control to <140/<90 mm Hg? A cross-sectional analysis of two cohorts. *BMJ Open*. 2025 Apr 7;15(4):e090440. doi: 10.1136/bmjopen-2024-090440. PMID: 40194880; PMCID: PMC11977477.
- Khan SS, Page C, Wojdyla DM, Schwartz YY, Greenland P, Pencina MJ. Predictive Utility of a Validated Polygenic Risk Score for Long-Term Risk of Coronary Heart Disease in Young and Middle-Aged Adults. *Circulation*. 2022 Aug 23;146(8):587-596. doi: 10.1161/CIRCULATIONAHA.121.058426. Epub 2022 Jul 26. PMID: 35880530; PMCID: PMC9398962.
- O'Connor, Elizabeth A., et al. "Behavioral counseling to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: updated evidence report and systematic review for the US Preventive Services Task Force." *Jama* 324.20 (2020): 2076-2094.

Please fill out our survey!

Find the survey link in the chat and again at the close of the webinar.

Your feedback is very valuable and helps us to provide the CHCANYS network with relevant and engaging content.





Thank you!

COMMUNITY
HEALTH CARE
ASSOCIATION
of New York State

chcanys.org